Neuro-Behcet'
Conditions
Interventions
None listed
Sponsors
Yokohama City University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Case reports, case series, case-control studies, cohort studies, and randomized clinical trials are eligible. (2) Studies involving patients clinically diagnosed with neuro-Behcet's disease are eligible. (3) Studies evaluating the efficacy and safety of IL-6 inhibitors in neuro-Behcet's disease are eligible.
Exclusion criteria
Exclusion criteria: (1) Systematic reviews or meta-analysis papers. (2) Republished research literature will be excluded unless it contains new findings related to the efficacy or safety of IL-6 inhibitors. (3) Research published in languages other than English.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete Remission Rate: The proportion of patients meeting all of the following criteria: Complete resolution of clinical symptoms of neuro-Behcet's disease Normalization of C-reactive protein (CRP) levels Resolution of brain lesions on MRI (disappearance of contrast-enhanced lesions) Prednisolone maintenance dose =< 0.1 mg/kg/day Absence of neurological sequelae (modified Rankin Scale <1) | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in prednisolone dosage Improvement in inflammatory markers and disease activity Improvement in quality of life (QOL) Relapse rate Adverse events (safety outcomes) | — |
Countries
Japan
Contacts
Public ContactKaoru Minegishi
Yokohama City University Graduate School of Medicine Department of Stem Cell and Immune Regulation
Outcome results
None listed